Protein testing in patients with multiple myeloma a review of clinical effectiveness and guidelines

Protein manifestations characteristic of multiple myeloma (MM) include increases of monoclonal (M)-protein concentrations (IgG, IgA, IgA, IgD), light chain concentrations (including kappa [ð] and lambda, abnormal ø2-microglobulin, serum albumin, creatinine, and hemoglobin levels, and findings of bon...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 09 January 2015, 2015
Series:Rapid response report: summary with critical appraisal
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:Protein manifestations characteristic of multiple myeloma (MM) include increases of monoclonal (M)-protein concentrations (IgG, IgA, IgA, IgD), light chain concentrations (including kappa [ð] and lambda, abnormal ø2-microglobulin, serum albumin, creatinine, and hemoglobin levels, and findings of bone marrow plasma cells (of greater than or equal to 5%). Measurement of the protein manifestations produced by patients can be achieved by numerous methods. Traditional tests that measure M-proteins are the 24-hour urine collection test, urine protein electrophoresis (UPEP), serum protein electrophoresis (SPEP), and immunofixation electrophoresis (IFE). One newer test (developed in 2001) is the serum free light chain (sFLC) assay. The frequency with which to test using any of the tests along with the clinical utility of the newer tests remains in question. It is for this reason that a review of the clinical effectiveness, clinical utility, and guidelines of repeat testing for protein abnormalities in patients with MM was undertaken
Item Description:Title from PDF caption
Physical Description:1 PDF file (38 pages) illustrations